|1.||Zyuzin, Jekaterina: 1 article (05/2014)|
|2.||Charles, Andrew: 1 article (05/2014)|
|3.||Smith, Monique L: 1 article (05/2014)|
|4.||Pradhan, Amynah A: 1 article (05/2014)|
|5.||Molino, Lory: 1 article (04/2009)|
|6.||Dax, Scott L: 1 article (04/2009)|
|7.||Stone, Dennis J: 1 article (04/2009)|
|8.||Colburn, Raymond W: 1 article (04/2009)|
|9.||Zhang, Sui-Po: 1 article (04/2009)|
|10.||Codd, Ellen E: 1 article (04/2009)|
04/01/2009 - "Coupled with the previously published lack of self-administration behavior of the compound by alfentanil-trained primates, these findings strongly recommend delta-opioid agonists such as JNJ-20788560 for the relief of inflammatory hyperalgesia."
05/01/2014 - "Three different δ-opioid receptor agonists, SNC80, ARM390 and JNJ20788560, significantly reduced NTG-evoked hyperalgesia. "
|2.||Respiratory Insufficiency (Respiratory Failure)
04/01/2009 - "Unlike morphine, JNJ-20788560 did not exhibit respiratory depression (blood gas analysis), and no withdrawal signs were precipitated by the administration of opioid (mu or delta) antagonists. "
04/01/2009 - "JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence."
|1.||delta Opioid Receptors (delta Opioid Receptor)
|3.||Opioid Receptors (Opioid Receptor)
|4.||Morphine (MS Contin)
|5.||4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamide
|1.||Self Administration (Administration, Self)